Swiss drugmaker Roche has again extended the deadline for its tender offer for Spark Therapeutics, saying US and UK anti-trust authorities needed more time to review the deal.
The offer, which was originally due to expire on 25 November, has now been extended to 10 December. Roche says that the terms and conditions of the offer remain the same. So far 14.8% of the shares were tendered.
Roche has put back the deadline several times since it announced the US$4.3bn offer to buy the gene therapy company in February.
